Drug Development

Our drug development program focuses on drug repurposing – testing existing drugs to see if they can also be beneficial for vitiligo patients. Historical examples of repurposing from global pharma provide a clear precedent for our own repurposing activities, suggesting that success is possible. 

This is proving particularly fruitful in the search for new treatments for non-life threatening diseases such as vitiligo, which are often neglected by the research community. 

The scientific rationale behind drug repurposing is supported by two core scientific concepts.

  • A single drug often interacts with multiple targets
  • Targets relevant to one disease or biological process are often involved in several biological processes.

We are currently in the first stage of the program, where we are focusing on off-label use of approved drugs already on the market and thus available to vitiligo patients immediately. 

Such an approach would minimize a complex, multi-year and multi-million dollar study necessary at an early drug development stage. The most promising compounds and drugs will be tested in pre-clinical trials to evaluate their ability to slow or stop the vitiligo progression and induce repigmentation.

Such an approach would minimize a complex, multi-year and multi-million dollar study necessary at an early drug development stage. The most promising compounds and drugs will be tested in pre/clinical trials to evaluate their ability to slow or stop the vitiligo progression and induce regimentation.

Recent Results

Promising results from our drug re-purposing program were presented at the EADV Spring Symposium on May 24, 2013. These showed that Sodium Oxodihydroacridinylacetate, an active ingredient of NEOVIR produced by Pharmsyntez in Russia, is effective in stopping vitiligo progression. Read more  here.

image description

I support the petition to designate June 25 as Vitiligo World Day and save millions of people worldwide from social isolation and persecution.

To download this free file, please tell us a little bit about yourself.

Close